These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18310291)

  • 21. In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters.
    Luque RM; Sampedro-Nuñez M; Gahete MD; Ramos-Levi A; Ibáñez-Costa A; Rivero-Cortés E; Serrano-Somavilla A; Adrados M; Culler MD; Castaño JP; Marazuela M
    Oncotarget; 2015 Aug; 6(23):19619-33. PubMed ID: 26124083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity in signaling pathways of gastroenteropancreatic neuroendocrine tumors: a critical look at notch signaling pathway.
    Wang H; Chen Y; Fernandez-Del Castillo C; Yilmaz O; Deshpande V
    Mod Pathol; 2013 Jan; 26(1):139-47. PubMed ID: 22918166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular and Cell Biological Aspects of Gastroenteropancreatic Neuroendocrine Tumor Disease. Conference proceedings. Berlin, Germany, November 3-7, 1993.
    Ann N Y Acad Sci; 1994 Sep; 733():1-535. PubMed ID: 7978857
    [No Abstract]   [Full Text] [Related]  

  • 24. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
    Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. O
    Watanabe H; Yamazaki Y; Fujishima F; Izumi K; Imamura M; Hijioka S; Toriyama K; Yatabe Y; Kudo A; Motoi F; Unno M; Sasano H
    BMC Cancer; 2020 Dec; 20(1):1195. PubMed ID: 33287738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
    Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
    Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.
    Asa SL; La Rosa S; Basturk O; Adsay V; Minnetti M; Grossman AB
    Endocr Pathol; 2021 Mar; 32(1):169-191. PubMed ID: 33459926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors.
    Arnason T; Sapp HL; Rayson D; Barnes PJ; Drewniak M; Nassar BA; Huang WY
    Arch Pathol Lab Med; 2011 Dec; 135(12):1539-44. PubMed ID: 22129180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors.
    Klöppel G; Anlauf M; Perren A
    Endocr Pathol; 2007; 18(3):150-5. PubMed ID: 18058264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autocrine growth inhibition by transforming growth factor beta-1 (TGFbeta-1) in human neuroendocrine tumour cells.
    Wimmel A; Wiedenmann B; Rosewicz S
    Gut; 2003 Sep; 52(9):1308-16. PubMed ID: 12912863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.
    Chatani PD; Agarwal SK; Sadowski SM
    Front Endocrinol (Lausanne); 2020; 11():575620. PubMed ID: 33537001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.
    Waser B; Rehmann R; Sanchez C; Fourmy D; Reubi JC
    J Clin Endocrinol Metab; 2012 Feb; 97(2):482-8. PubMed ID: 22112810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors).
    Oberg K
    Curr Opin Endocrinol Diabetes Obes; 2009 Feb; 16(1):72-8. PubMed ID: 19115524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.
    Camilli M; Papadimitriou K; Nogueira A; Incorvaia L; Galvano A; D'Antonio F; Ferri J; Santini D; Silvestris N; Russo A; Peeters M; Rolfo C
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):471-478. PubMed ID: 29629846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract.
    Kayed H; Kleeff J; Ding J; Hammer J; Giese T; Zentgraf H; Büchler MW; Friess H
    Histol Histopathol; 2004 Oct; 19(4):1021-31. PubMed ID: 15375745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms.
    Briest F; Grabowski P
    Cancer Treat Rev; 2015 May; 41(5):423-30. PubMed ID: 25837868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors.
    Miki M; Oono T; Fujimori N; Takaoka T; Kawabe K; Miyasaka Y; Ohtsuka T; Saito D; Nakamura M; Ohkawa Y; Oda Y; Suyama M; Ito T; Ogawa Y
    Cancer Med; 2019 Jul; 8(8):3748-3760. PubMed ID: 31129920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.